Higher OAK (Oral Anticoagulation Knowledge) Score at Baseline Associated with Better TTR (Time in Therapeutic Range) in Patients Taking Warfarin
Overview
Authors
Affiliations
A lack in patient knowledge of warfarin therapy is associated with poor adherence. This knowledge gap may result in a lower INR Time in Therapeutic Range (TTR). To investigate association between patient anticoagulation knowledge and warfarin control. Michigan Anticoagulation Quality Improvement Initiative (MAQI) is a Blue Cross Blue Shield of Michigan sponsored consortium of six anticoagulation management services. Patients prescribed warfarin at two MAQI sites completed a voluntary Oral Anticoagulation Knowledge (OAK) questionnaire at warfarin initiation and 6-month follow-up. The results of 20 OAK questions and TTRs (excluding 1st month post-initiation) were compared using chi-square tests, t-tests and multivariate analysis adjusting for SAMe-TTR and days on warfarin. Of 1836 surveys distributed at warfarin initiation, 481 (26.2%) patients completed the baseline questionnaire (within 1 month post-initiation): mean OAK score: 14.6 ± 3.4. Of those, 147 (30.6%) completed 6-month follow-up surveys (OAK: 12.7 ± 5.8). Patients with TTR ≥ 70% at baseline scored higher on OAK tests than patients with TTR < 70% in unadjusted analyses (15.1 ± 3.2 v. 14.2 ± 3.5, p = 0.003) and adjusted analysis (p = 0.020). There was no unadjusted or adjusted difference in OAK scores at 6-month follow-up between patients with TTR ≥ 70% and TTR < 70%. For patients who completed baseline and follow-up surveys, there was a decrease of 2.4 points in OAK score between baseline and 6-month follow up (p < 0.001). Higher baseline, but not follow-up, OAK score is associated with better warfarin control and average OAK scores decreased between baseline and follow-up. Further studies are needed to determine what type of patient education may improve patient knowledge retention and warfarin control.
Kokash N, Gharaibeh L, Al Zoubi S BMC Res Notes. 2025; 18(1):98.
PMID: 40038778 PMC: 11881488. DOI: 10.1186/s13104-025-07167-6.
Tadesse T, Yadeta D, Chelkeba L, Gebremedhin A, Gedif Fenta T Clin Appl Thromb Hemost. 2024; 30:10760296241260736.
PMID: 38863211 PMC: 11179514. DOI: 10.1177/10760296241260736.
Praxedes M, Silva J, Cruz A, Viana C, Barbosa H, Guimaraes N PLoS One. 2023; 18(8):e0289836.
PMID: 37561771 PMC: 10414645. DOI: 10.1371/journal.pone.0289836.
Thromboprophylaxis for Coagulopathy Related to COVID-19 in Pediatrics: A Narrative Review.
Sahrai H, Hemmati-Ghavshough M, Shahrabi M, Jafari-Rouhi A, Solduzian M Paediatr Drugs. 2023; 25(4):443-452.
PMID: 37142896 PMC: 10158690. DOI: 10.1007/s40272-023-00566-x.